Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

55.6%

-30.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

120%

6 of 5 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03825094Unknown

DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry

Role: lead

NCT03715452Completed

DyeVert™ Plus Contrast Reduction System Multicenter Observational Study

Role: lead

NCT03118544Terminated

REduction of Contrast Via DyeVert Used in CTO Procedures

Role: collaborator

NCT02752802Not ApplicableCompleted

DyeVert System RCT

Role: lead

NCT01976299Not ApplicableCompleted

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

Role: lead

NCT01168024Not ApplicableTerminated

Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)

Role: lead

NCT02606734Not ApplicableCompleted

DyeVert Pilot Trial

Role: lead

NCT02158442Phase 2Completed

Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients

Role: lead

NCT02436642Terminated

AVERT Plus Post-Market Registry

Role: lead

NCT02434055Terminated

Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS

Role: collaborator

All 10 trials loaded